Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:
Douglas D. Richman, MD (Co-Chair)
Dr Richman reported consulting or advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and Gilead Sciences, Inc. (Updated January 23, 2024)
Paul A. Volberding, MD (Co-Chair)
DDr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 02/08/23)
Roger J. Bedimo, MD, MS
Dr Bedimo reported receiving research grants/grants pending awarded to his institution from Merck & Co, Inc, and serving on the scientific advisory board for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc., Shionogi, and Janssen Pharmaceuticals. (Updated February 12, 2024)
Constance A. Benson, MD
Dr Benson reported receiving research grants awarded to her institution from Gilead Sciences, Inc, and serving as a consultant to NDA Partners, LLC. (Updated February 20, 2024)
Judith S. Currier, MD
Dr Currier reported consulting or advisor fees from Merck & Co, Inc. (Updated February 29, 2024)
Carlos del Rio, MD
Dr del Rio reported receiving consulting fees from Roche Diagnostics. (Updated January 30, 2024)
Ellen F. Eaton, MD
Dr Eaton reported receiving consulting fees from Gilead Sciences. (Updated February 6, 2024)
Rajesh T. Gandhi, MD
Dr Gandhi reported no relevant financial relationships with ineligible companies. (Updated March 29, 2024)
Donna M. Jacobsen, BS
Ms Jacobsen reported no relevant financial affiliations with ineligible companies to disclose. (Updated May 16, 2024)
Raphael J. Landovitz, MD
Dr Landovitz reported serving on scientific advisory boards and as a consultant for Merck & Co., Inc, Gilead Sciences, Inc, ViiV Healthcare, and RedQueen Therapeutics. (Updated February 21, 2024)
Susanna Naggie, MD
Dr Naggie reported consulting fees from Bristol-Myers Squibb, Personal health Insights, Inc, and Vir Biotechnology. She reported having stock options for Vir Biotechnlogy. (Updated March 6, 2024)
Michael S. Saag, MD
Dr Saag reported serving as a consultant for TFF Pharmaceuticals, Inc, and American Gene Technologies International, Inc. (Updated March 11, 2024)
Robert T. Schooley, MD
Dr Schooley reported receiving consulting fees from AbbVie, Inc, Merck & Co, Inc, and Vir Biotechnology. (Updated March 6, 2024)